43 results on '"Eek C"'
Search Results
2. P789Association of sensitive Troponin I and left ventricular contractile function in patients with stable coronary artery disease
- Author
-
Smedsrud, M K, Gravning, J, Eek, C, Morkrid, L, Skulstad, H, Aaberge, L, Bendz, B, Kjekshus, J, and Edvardsen, T
- Published
- 2011
3. Time from ECG Diagnosis to sheath insertion is a strong predictor for mortality in patients with ST elevation myocardial infarction admitted for primary percutaneous coronary intervention
- Author
-
Larsen, A.I, primary, Loland, K, additional, Hovland, S, additional, Bleie, O, additional, Trovik, T, additional, Hegbom, K, additional, Larsen, T, additional, Fossum, E, additional, Eek, C, additional, Moer, R, additional, Juliebo, V, additional, Uchto, M, additional, and Rotevatn, S, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Teri-LIFE: an observational study of quality of life in patients with relapsing remitting multiple sclerosis treated with teri-flunomide in the Nordic region
- Author
-
Hestvik, A. L., Frederiksen, J., Helle Hvilsted Nielsen, Torkildsen, O., Eek, C., Huang-Link, Y., Haghighi, S., Poole, E. M., Tsai, J. A., and Kant, M.
- Abstract
Title (max. 250 characters including spaces): 151 Teri-LIFE: An observational study of quality of life in patients with relapsing remitting multiple sclerosis treated with teriflunomide in the Nordic region Authors: Hestvik AL,1 Frederiksen J,2 Nielsen HH,3 Torkildsen Ø,4 Eek C,5 Huang-Link Y,6 Haghighi S,7 Poole EM,8 Tsai JA,9 Kant M3 1Sanofi, Lysaker, Norway 2University of Copenhagen, Copenhagen, Denmark 3University of Southern Denmark, Odense, Denmark 4Haukeland University Hospital, Bergen, Norway 5Drammen Hospital, Drammen, Norway 6 Linköping University Hospital, Linköping, Sweden 7Department of Neurology, Motala Hospital, Motala, Sweden 8Sanofi, Cambridge, MA, USA 9Sanofi, Stockholm, Sweden Abstract character count (max. 2500 including spaces, excluding disclosures): 2441 Introduction Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing forms of multiple sclerosis (MS) or relapsing remitting MS (RRMS), depending on the local label. Objective To report the results of Teri-LIFE, a non-interventional, real-world study of quality of life (QoL) in patients with RRMS treated with teriflunomide in the Nordic region. Methods Teri-LIFE recruited patients from Norway, Sweden, and Denmark between June 2015 and December 2016. Patients ≥18 years of age with RRMS who had already chosen to initiate treatment with teriflunomide 14 mg were eligible. Patients were followed per routine clinical practice for 24 months, with follow-up every 6 months. The primary endpoint was QoL measured by the Short Form-36 (SF-36) questionnaire. Secondary endpoints included clinical efficacy, safety, and adherence. Results Two hundred patients were recruited, 68% were treatment-naïve. The majority (71%) were female, mean (standard deviation [SD]) age was 44.1 (10.4) years. Mean (SD) time since diagnosis was 3.6 (5.9) years. Median (upper quartile, lower quartile) Expanded Disability Status Scale score was 2.0 (1.0, 2.5). Mean (SD) number of relapses in the prior 2 years was 0.8 (0.7); 69/197 (35%) patients reported no relapses during this time. A total of 118 (59%) patients remained on teriflunomide during the 24-month study period; 22% discontinued due to adverse events (AEs), 9% due to lack of efficacy, and 10% due to other reasons. Mean (SD) SF-36 scores at baseline and months 6, 12, 18 and 24 were 46.5 (10.0), 46.7 (10.4), 47.5 (9.7), 47.6 (10.5), and 47.7 (10.4), respectively, for the physical component score (PCS), and 46.6 (11.8), 48.6 (11.9), 48.4 (11.1), 48.4 (11.2), and 48.8 (10.3), respectively, for the mental component score (MCS). A repeated measures analysis of covariance showed no significant change except for baseline to 24 months on the PCS (P=0.0038). The on-treatment annualised relapse rate (95% confidence interval) was 0.17 (0.13, 0.23); 79% of patients experienced no relapses. AEs were reported by 93.5% of patients, the most common being hair thinning (26.5%), diarrhoea (23%), and fatigue (20%). Serious AEs were reported by 11% of patients. Conclusions QoL was stable over 24 months in teriflunomide-treated patients. The benefit–risk ratio, and safety and tolerability profile of teriflunomide were consistent with those observed in clinical trials. Disclosures: ALH: Employee of Sanofi JF: Served on scientific advisory boards for and received funding for travel related to these activities as well as honoraria from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva, Novartis and Almirall. Received speaker honoraria from Biogen Idec, Teva and Novartis. HHN: Accepted financial compensation and travel reimbursements from Teva, Biogen Idec, Sanofi-Genzyme, Novartis and Roche. ØT: Served on the scientific advisory boards for and received speaker honoraria from Novartis, Biogen, Genzyme, Roche and Merck. CE: Received honorarium from Merck and contributed to sponsored research. YL: Financial support from Sanofi for research (Teri-LIFE study) SH: The Teri-LIFE project received financial support from Sanofi. EMP: Employee of Sanofi with ownership interest JAT: Employee of Sanofi with ownership interest MK: Support for congress participation from Biogen, Genzyme, Teva, Roche, and Novartis Study supported by Sanofi Submission details Type: Oral or poster presentation Abstract category: Clinical aspects of MS 1. Diagnosis and differential diagnosis 2. MS Variants 3. Paediatric MS 4. Progressive MS 5. Natural course 6. Epidemiology 7. MS and gender 8. Pregnancy in MS 9. MS symptoms 10. Clinical assessment tools 11. Patient reported outcomes 12. Economic burden 13. Neuro-ophthalmology 14. Comorbidity Pathology and pathogenesis of MS 15. Pathology 16. Experimental models 17. Genetics/ Epigenetics 18. Immunology 19. Microbiology and virology 20. Environmental factors 21. Neurobiology 22. Neurodegeneration 23. Repairing mechanisms 24. MRI and PET 25. OCT 26. Neuropsychology 27. Biomarkers Therapy 28. Immunomodulation/ Immunosuppression 29. Neuroprotection & repair 30. Long-term treatment monitoring 31. Risk management for disease modifying treatments 32. Tools for detecting therapeutic response 33. Symptomatic treatment 34. Others RIMS 35. Multi-disciplinary rehabilitation 36. Symptoms management (including cognition, fatigue, imbalance) 37. Neurobiology & rehabilitation Presenting author details: Anne Lise Hestvik, Sanofi, Prof Kohtsvei 5–17, 1366 Lysaker, Norway. Email: annelise.hestvik@sanofi.com. Telephone: +47 97 48 99 64.
- Published
- 2019
- Full Text
- View/download PDF
5. P1749Mortality in ST segment elevation myocardial infarction treated with primary percutaneous intervention in Norway A report from the Norwegian registry of invasive cardiology (NORIC)
- Author
-
Larsen, A I, primary, Loland, K H, additional, Hovland, S, additional, Eek, C, additional, Fossum, E, additional, Trovik, T, additional, Uchto, M, additional, Hegbom, K, additional, Larsen, T, additional, Moer, R, additional, and Rotevatn, S, additional
- Published
- 2019
- Full Text
- View/download PDF
6. P2751Mechanical dispersion as marker of left ventricular dysfunction and prognosis in stable coronary artery disease
- Author
-
Havneraas Kvisvik, B A, primary, Aagaard, E N, additional, Morkrid, L, additional, Rosjo, H, additional, Smedsrud, M K, additional, Eek, C, additional, Benz, B, additional, Haugaa, K H, additional, Edvardsen, T, additional, and Gravning, J, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER)
- Author
-
Holm, N. R., Andreasen, L. N., Walsh, S., Kajander, O. A., Witt, N., Eek, C., Knaapen, P., Koltowski, L., Gutierrez-Chico, J. L., Burzotta, Francesco, Kockman, J., Ormiston, J., Santos-Pardo, I., Laanmets, P., Mylotte, D., Madsen, M., Hjort, J., Kumsars, I., Ramunddal, T., Christiansen, E. H., Burzotta F. (ORCID:0000-0002-6569-9401), Holm, N. R., Andreasen, L. N., Walsh, S., Kajander, O. A., Witt, N., Eek, C., Knaapen, P., Koltowski, L., Gutierrez-Chico, J. L., Burzotta, Francesco, Kockman, J., Ormiston, J., Santos-Pardo, I., Laanmets, P., Mylotte, D., Madsen, M., Hjort, J., Kumsars, I., Ramunddal, T., Christiansen, E. H., and Burzotta F. (ORCID:0000-0002-6569-9401)
- Abstract
Background Percutaneous coronary intervention in complex bifurcation lesions is prone to suboptimal implantation results and is associated with increased risk of subsequent clinical events. Angiographic ambiguity is high during bifurcation stenting, but it is unknown if procedural guidance by intravascular optical coherence tomography (OCT) improves clinical outcome.Methods and design OCTOBER is a randomized, investigator-initiated, multicenter trial aimed to show superiority of OCT-guided stent implantation compared to standard angiographic-guided implantation in bifurcation lesions. The primary outcome measure is a 2-year composite end point of cardiac death, target lesion myocardial infarction, and ischemia-driven target lesion revascularization. The calculated sample size is 1,200 patients in total, and allocation is 1: 1. Eligible patients have stable or unstable angina pectoris or stabilized non-ST elevation myocardial infarction, and a coronary bifurcation lesion with significant main vessel stenosis and more than 50 % stenosis in a side branch with a reference diameter >= 2.5mm. Treatment is performed by the provisional side branch stenting technique or 2-stent techniques, and the systematic OCT guiding protocol is aimed to evaluate (1) plaque preparation, (2) lesion length, (3) segmental reference sizes, (4) lesion coverage, (5) stent expansion, (6) malapposition, (7) wire positions, and (8) ostial results.
- Published
- 2018
8. Early systolic lengthening may identify minimal myocardial damage in patients with non-ST-elevation acute coronary syndrome
- Author
-
Zahid, W., primary, Eek, C. H., additional, Remme, E. W., additional, Skulstad, H., additional, Fosse, E., additional, and Edvardsen, T., additional
- Published
- 2014
- Full Text
- View/download PDF
9. Mitral annular excursion in patients with suspected non-ST-elevation acute coronary syndrome can identify coronary occlusion and predict mortality
- Author
-
Zahid, W., Johnson, Jonas, Westholm, C., Eek, C., Skulstad, R., Fosse, E., Winter, Reider, Edvardsen, T., Zahid, W., Johnson, Jonas, Westholm, C., Eek, C., Skulstad, R., Fosse, E., Winter, Reider, and Edvardsen, T.
- Abstract
QC 20121012
- Published
- 2012
10. Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area
- Author
-
Wang, M., primary, Yan, G., additional, Yue, W., additional, Siu, C., additional, Tse, H., additional, Perperidis, A., additional, Cusack, D., additional, White, A., additional, Macgillivray, T., additional, Mcdicken, W., additional, Anderson, T., additional, Ryabov, V., additional, Shurupov, V., additional, Suslova, T., additional, Markov, V., additional, Elmstedt, N., additional, Ferm Widlund, K., additional, Lind, B., additional, Brodin, L.-A., additional, Westgren, M., additional, Mantovani, F., additional, Barbieri, A., additional, Bursi, F., additional, Valenti, C., additional, Quaglia, M., additional, Modena, M., additional, Peluso, D., additional, Muraru, D., additional, Dal Bianco, L., additional, Beraldo, M., additional, Solda', E., additional, Tuveri, M., additional, Cucchini, U., additional, Al Mamary, A., additional, Badano, L., additional, Iliceto, S., additional, Goncalves, A., additional, Almeria, C., additional, Marcos-Alberca, P., additional, Feltes, G., additional, Hernandez-Antolin, R., additional, Rodriguez, H., additional, Maroto, L., additional, Silva Cardoso, J., additional, Macaya, C., additional, Zamorano, J., additional, Squarciotta, S., additional, Innocenti, F., additional, Guzzo, A., additional, Bianchi, S., additional, Lazzeretti, D., additional, De Villa, E., additional, Vicidomini, S., additional, Del Taglia, B., additional, Donnini, C., additional, Pini, R., additional, Mennie, C., additional, Salmasi, A. M., additional, Kutyifa, V., additional, Nagy, V., additional, Edes, E., additional, Apor, A., additional, Merkely, B., additional, Nyrnes, S., additional, Lovstakken, L., additional, Torp, H., additional, Haugen, B., additional, Said, K., additional, Shehata, A., additional, Ashour, Z., additional, El-Tobgy, S., additional, Cameli, M., additional, Bigio, E., additional, Lisi, M., additional, Righini, F., additional, Franchi, F., additional, Scolletta, S., additional, Mondillo, S., additional, Gayat, E., additional, Weinert, L., additional, Yodwut, C., additional, Mor-Avi, V., additional, Lang, R., additional, Hrynchyshyn, N., additional, Kachenoura, N., additional, Diebold, B., additional, Khedim, R., additional, Senesi, M., additional, Redheuil, A., additional, Mousseaux, E., additional, Perdrix, L., additional, Yurdakul, S., additional, Erdemir, V., additional, Tayyareci, Y., additional, Memic, K., additional, Yildirimturk, O., additional, Aytekin, V., additional, Gurel, M., additional, Aytekin, S., additional, Gargani, L., additional, Fernandez Cimadevilla, C., additional, La Falce, S., additional, Landi, P., additional, Picano, E., additional, Sicari, R., additional, Smedsrud, M. K., additional, Gravning, J., additional, Eek, C., additional, Morkrid, L., additional, Skulstad, H., additional, Aaberge, L., additional, Bendz, B., additional, Kjekshus, J., additional, Edvardsen, T., additional, Bajraktari, G., additional, Hyseni, V., additional, Morina, B., additional, Batalli, A., additional, Tafarshiku, R., additional, Olloni, R., additional, Henein, M., additional, Mjolstad, O., additional, Snare, S., additional, Folkvord, L., additional, Helland, F., additional, Haraldseth, O., additional, Grimsmo, A., additional, Berry, M., additional, Zaghden, O., additional, Nahum, J., additional, Macron, L., additional, Lairez, O., additional, Damy, T., additional, Bensaid, A., additional, Dubois Rande, J., additional, Gueret, P., additional, Lim, P., additional, Nciri, N., additional, Issaoui, Z., additional, Tlili, C., additional, Wanes, I., additional, Foudhil, H., additional, Dachraoui, F., additional, Grapsa, J., additional, Dawson, D., additional, Nihoyannopoulos, P., additional, Gianturco, L., additional, Turiel, M., additional, Atzeni, F., additional, Sarzi-Puttini, P., additional, Stella, D., additional, Donato, L., additional, Tomasoni, L., additional, Jung, P., additional, Mueller, M., additional, Huber, T., additional, Sevilmis, G., additional, Kroetz, F., additional, Sohn, H., additional, Panoulas, V., additional, Bratsas, A., additional, Raso, R., additional, Tartarisco, G., additional, Pioggia, G., additional, Gargiulo, P., additional, Petretta, M., additional, Cuocolo, A., additional, Prastaro, M., additional, D'amore, C., additional, Vassallo, E., additional, Savarese, G., additional, Marciano, C., additional, Paolillo, S., additional, Perrone Filardi, P., additional, Aggeli, C., additional, Felekos, I., additional, Roussakis, G., additional, Poulidakis, E., additional, Pietri, P., additional, Toutouzas, K., additional, Stefanadis, C., additional, Kaladaridis, A., additional, Skaltsiotis, I., additional, Kottis, G., additional, Bramos, D., additional, Takos, D., additional, Matthaios, I., additional, Agrios, I., additional, Papadopoulou, E., additional, Moulopoulos, S., additional, Toumanidis, S., additional, Carrilho-Ferreira, P., additional, Cortez-Dias, N., additional, Jorge, C., additional, Silva, D., additional, Silva Marques, J., additional, Placido, R., additional, Santos, L., additional, Ribeiro, S., additional, Fiuza, M., additional, Pinto, F., additional, Stoickov, V., additional, Ilic, S., additional, Deljanin Ilic, M., additional, Kim, W., additional, Woo, J., additional, Bae, J., additional, Kim, K., additional, Descalzo, M., additional, Rodriguez, J., additional, Moral, S., additional, Otaegui, I., additional, Mahia, P., additional, Garcia Del Blanco, L., additional, Gonzalez Alujas, T., additional, Figueras, J., additional, Evangelista, A., additional, Garcia-Dorado, D., additional, Takeuchi, M., additional, Kaku, K., additional, Otani, K., additional, Iwataki, M., additional, Kuwaki, H., additional, Haruki, N., additional, Yoshitani, H., additional, Otsuji, Y., additional, Kukucka, M., additional, Pasic, M., additional, Unbehaun, A., additional, Dreysse, S., additional, Mladenow, A., additional, Kuppe, H., additional, Hetzer, R., additional, Rajamannan, N., additional, Tanrikulu, A., additional, Kristiansson, L., additional, Gustafsson, S., additional, Lindmark, K., additional, Henein, M. Y., additional, Evdoridis, C., additional, Stougiannos, P., additional, Thomopoulos, M., additional, Fosteris, M., additional, Spanos, P., additional, Sionis, G., additional, Giatsios, D., additional, Paschalis, A., additional, Sakellaris, C., additional, Trikas, A., additional, Yong, Z. Y., additional, Boerlage-Van Dijk, K., additional, Koch, K., additional, Vis, M., additional, Bouma, B., additional, Piek, J., additional, Baan, J., additional, Abid, L., additional, Frikha, Z., additional, Makni, K., additional, Maazoun, N., additional, Abid, D., additional, Hentati, M., additional, Kammoun, S., additional, Barbier, P., additional, Staron, A., additional, Cefalu', C., additional, Berna, G., additional, Gripari, P., additional, Andreini, D., additional, Pontone, G., additional, Pepi, M., additional, Ring, L., additional, Rana, B., additional, Ho, S., additional, Wells, F., additional, Dogan, A., additional, Karaca, O., additional, Guler, G., additional, Guler, E., additional, Gunes, H., additional, Alizade, E., additional, Agus, H., additional, Gol, G., additional, Esen, O., additional, Esen, A., additional, Turkmen, M., additional, Agricola, E., additional, Ingallina, G., additional, Ancona, M., additional, Maggio, S., additional, Slavich, M., additional, Tufaro, V., additional, Oppizzi, M., additional, Margonato, A., additional, Orsborne, C., additional, Irwin, B., additional, Pearce, K., additional, Ray, S., additional, Garcia Alonso, C., additional, Vallejo, N., additional, Labata, C., additional, Lopez Ayerbe, J., additional, Teis, A., additional, Ferrer, E., additional, Nunez Aragon, R., additional, Gual, F., additional, Pedro Botet, M., additional, Bayes Genis, A., additional, Santos, C. M., additional, Carvalho, M., additional, Andrade, M., additional, Dores, H., additional, Madeira, S., additional, Cardoso, G., additional, Ventosa, A., additional, Aguiar, C., additional, Ribeiras, R., additional, Mendes, M., additional, Petrovic, M., additional, Milasinovic, G., additional, Vujisic-Tesic, B., additional, Nedeljkovic, I., additional, Zamaklar-Trifunovic, D., additional, Petrovic, I., additional, Draganic, G., additional, Banovic, M., additional, Boricic, M., additional, Villarraga, H., additional, Molini-Griggs Bs, C., additional, Silen-Rivera Bs, P., additional, Payne Mph Ms, B., additional, Koshino Md Phd, Y., additional, Hsiao Md, J., additional, Monivas Palomero, V., additional, Mingo Santos, S., additional, Mitroi, C., additional, Garcia Lunar, I., additional, Garcia Pavia, P., additional, Castro Urda, V., additional, Toquero, J., additional, Gonzalez Mirelis, J., additional, Cavero Gibanel, M., additional, Fernandez Lozano, I., additional, Oko-Sarnowska, Z., additional, Wachowiak-Baszynska, H., additional, Katarzynska-Szymanska, A., additional, Trojnarska, O., additional, Grajek, S., additional, Bellavia, D., additional, Pellikka, P., additional, Dispenzieri, A., additional, Oh, J. K., additional, Polizzi, V., additional, Pitrolo, F., additional, Musumeci, F., additional, Miller, F., additional, Ancona, R., additional, Comenale Pinto, S., additional, Caso, P., additional, Severino, S., additional, Cavallaro, C., additional, Vecchione, F., additional, D'onofrio, A., additional, Calabro', R., additional, Maceira Gonzalez, A. M., additional, Ripoll, C., additional, Cosin-Sales, J., additional, Igual, B., additional, Salazar, J., additional, Belloch, V., additional, Cosin-Aguilar, J., additional, Pinamonti, B., additional, Iorio, A., additional, Bobbo, M., additional, Merlo, M., additional, Barbati, G., additional, Massa, L., additional, Faganello, G., additional, Di Lenarda, A., additional, Sinagra, G. F., additional, Ishizu, T., additional, Seo, Y., additional, Enomoto, M., additional, Kameda, Y., additional, Ishibashi, N., additional, Inoue, M., additional, Aonuma, K., additional, Saleh, A., additional, Matsumori, A., additional, Negm, H., additional, Fouad, H., additional, Onsy, A., additional, Hamodraka, E., additional, Paraskevaidis, I., additional, Kallistratos, M., additional, Lezos, V., additional, Zamfir, T., additional, Manetos, C., additional, Mavropoulos, D., additional, Poulimenos, L., additional, Kremastinos, D., additional, Manolis, A., additional, Citro, R., additional, Rigo, F., additional, Ciampi, Q., additional, Patella, M., additional, Provenza, G., additional, Zito, C., additional, Tagliamonte, E., additional, Rotondi, F., additional, Silvestri, F., additional, Bossone, E., additional, Beltran Correas, P., additional, Gutierrez Landaluce, C., additional, Gomez Bueno, M., additional, Segovia Cubero, J., additional, Beladan, C., additional, Matei, F., additional, Popescu, B., additional, Calin, A., additional, Rosca, M., additional, Boanta, A., additional, Enache, R., additional, Savu, O., additional, Usurelu, C., additional, Ginghina, C., additional, Ciobanu, A. O., additional, Dulgheru, R., additional, Magda, S., additional, Dragoi, R., additional, Florescu, M., additional, Vinereanu, D., additional, Robalo Martins, S., additional, Calisto, C., additional, Goncalves, S., additional, Barrigoto, I., additional, Carvalho De Sousa, J., additional, Almeida, A., additional, Nunes Diogo, A., additional, Sargento, L., additional, Satendra, M., additional, Sousa, C., additional, Lousada, N., additional, Palma Reis, R., additional, Schiano Lomoriello, V., additional, Esposito, R., additional, Santoro, A., additional, Raia, R., additional, Schiattarella, P., additional, Dores, E., additional, Galderisi, M., additional, Mansencal, N., additional, Caille, V., additional, Dupland, A., additional, Perrot, S., additional, Bouferrache, K., additional, Vieillard-Baron, A., additional, Jouffroy, R., additional, Moceri, P., additional, Liodakis, E., additional, Gatzoulis, M., additional, Li, W., additional, Dimopoulos, K., additional, Sadron, M., additional, Seguela, P. E., additional, Arnaudis, B., additional, Dulac, Y., additional, Cognet, T., additional, Acar, P., additional, Shiina, Y., additional, Uemura, H., additional, Kupczynska, K., additional, Kasprzak, J., additional, Michalski, B., additional, Lipiec, P., additional, Carvalho, V., additional, Almeida, A. M. G., additional, David, C., additional, Marques, J., additional, Ferreira, P., additional, Amaro, M., additional, Costa, P., additional, Diogo, A., additional, Tritakis, V., additional, Ikonomidis, I., additional, Lekakis, J., additional, Tzortzis, S., additional, Kadoglou, N., additional, Papadakis, I., additional, Trivilou, P., additional, Koukoulis, C., additional, Anastasiou-Nana, M., additional, Bombardini, T., additional, Gherardi, S., additional, Arpesella, G., additional, Maccherini, M., additional, Serra, W., additional, Magnani, G., additional, Del Bene, R., additional, Pasanisi, E., additional, Startari, U., additional, Panchetti, L., additional, Rossi, A., additional, Piacenti, M., additional, Morales, M., additional, El Hajjaji, I., additional, El Mahmoud, R., additional, Digne, F., additional, Dubourg, O., additional, Agoston, G., additional, Moreo, A., additional, Pratali, L., additional, Moggi Pignone, A., additional, Pavellini, A., additional, Doveri, M., additional, Musca, F., additional, Varga, A., additional, Faita, F., additional, Rimoldi, S., additional, Sartori, C., additional, Alleman, Y., additional, Salinas Salmon, C., additional, Villena, M., additional, Scherrer, U., additional, Baptista, R., additional, Serra, S., additional, Castro, G., additional, Martins, R., additional, Salvador, M., additional, Monteiro, P., additional, Silva, J., additional, Szudi, L., additional, Temesvary, A., additional, Fekete, B., additional, Kassai, I., additional, Szekely, L., additional, Abdel Moneim, S. S., additional, Martinez, M., additional, Mankad, S., additional, Bernier, M., additional, Dhoble, A., additional, Chandrasekaran, K., additional, Oh, J., additional, Mulvagh, S., additional, Hong, G. R., additional, Kim, J. Y., additional, Lee, S. C., additional, Choi, S. H., additional, Sohn, I. S., additional, Seo, H. S., additional, Choi, J. H., additional, Cho, K. I., additional, Yoon, S. J., additional, Lim, S. J., additional, Wejner-Mik, P., additional, Kusmierek, J., additional, Plachcinska, A., additional, Szuminski, R., additional, Stoebe, S., additional, Tarr, A., additional, Trache, T., additional, Hagendorff, A., additional, Jenkins, C., additional, Kuhl, H., additional, Nesser, H., additional, Marwick, T., additional, Franke, A., additional, Niel, J., additional, Sugeng, L., additional, Soderberg, S., additional, Lindqvist, P., additional, Necas, J., additional, Kovalova, S., additional, Saha, S. K., additional, Kiotsekoglou, A., additional, Toole, R., additional, Govind, S., additional, Gopal, A., additional, Amzulescu, M.-S., additional, Florian, A., additional, Bogaert, J., additional, Janssens, S., additional, Voigt, J., additional, Parisi, V., additional, Losi, M., additional, Parrella, L., additional, Contaldi, C., additional, Chiacchio, E., additional, Caputi, A., additional, Scatteia, A., additional, Buonauro, A., additional, Betocchi, S., additional, Rimbas, R., additional, Mihaila, S., additional, Caputo, M., additional, Navarri, R., additional, Innelli, P., additional, Urselli, R., additional, Capati, E., additional, Ballo, P., additional, Furiozzi, F., additional, Favilli, R., additional, Lindquist, R., additional, Miller, A., additional, Reece, C., additional, O'leary, P., additional, Cetta, F., additional, Eidem, B. W., additional, Cikes, M., additional, Gasparovic, H., additional, Bijnens, B., additional, Velagic, V., additional, Kopjar, T., additional, Biocina, B., additional, Milicic, D., additional, Ta-Shma, A., additional, Nir, A., additional, Perles, Z., additional, Gavri, S., additional, Golender, J., additional, Rein, A., additional, Pinnacchio, G., additional, Barone, L., additional, Battipaglia, I., additional, Cosenza, A., additional, Marinaccio, L., additional, Coviello, I., additional, Scalone, G., additional, Sestito, A., additional, Lanza, G., additional, Crea, F., additional, Cakal, S., additional, Eroglu, E., additional, Ozkan, B., additional, Kulahcioglu, S., additional, Bulut, M., additional, Koyuncu, A., additional, Acar, G., additional, Alici, G., additional, Dundar, C., additional, Labombarda, F., additional, Zangl, E., additional, Pellissier, A., additional, Bougle, D., additional, Maragnes, P., additional, Milliez, P., additional, Saloux, E., additional, Lagoudakou, S., additional, Gialafos, E., additional, Tsokanis, A., additional, Nagy, A., additional, Kovats, T., additional, Vago, H., additional, Toth, A., additional, Sax, B., additional, Kovacs, A., additional, Elnoamany, M. F., additional, Badran, H., additional, Abdelfattah, I., additional, Khalil, T., additional, Salama, M., additional, Butz, T., additional, Taubenberger, C., additional, Thangarajah, F., additional, Meissner, A., additional, Van Bracht, M., additional, Prull, M., additional, Yeni, H., additional, Plehn, G., additional, Trappe, H., additional, Rydman, R., additional, Bone, D., additional, Alam, M., additional, Caidahl, K., additional, Larsen, F., additional, Gasior, Z., additional, Tabor, Z., additional, Sengupta, P., additional, Liu, D., additional, Niemann, M., additional, Hu, K., additional, Herrmann, S., additional, Stoerk, S., additional, Morbach, C., additional, Knop, S., additional, Voelker, W., additional, Ertl, G., additional, Weidemann, F., additional, Cawley, P., additional, Hamilton-Craig, C., additional, Mitsumori, L., additional, Maki, J., additional, Otto, C., additional, Astrom Aneq, M., additional, Nylander, E., additional, Ebbers, T., additional, Engvall, J., additional, Arvanitis, P., additional, Flachskampf, F., additional, Duvernoy, O., additional, De Torres Alba, F., additional, Valbuena Lopez, S., additional, Guzman Martinez, G., additional, Gomez De Diego, J., additional, Rey Blas, J., additional, Armada Romero, E., additional, Lopez De Sa, E., additional, Moreno Yanguela, M., additional, Lopez Sendon, J., additional, Trikalinos, N., additional, Siasos, G., additional, Aggeli, A., additional, Tomaszewski, A., additional, Kutarski, A., additional, Tomaszewski, M., additional, Vriz, O., additional, Driussi, C., additional, Bettio, M., additional, Pavan, D., additional, Antonini Canterin, F., additional, Doltra Magarolas, A., additional, Fernandez-Armenta, J., additional, Silva, E., additional, Solanes, N., additional, Rigol, M., additional, Barcelo, A., additional, Mont, L., additional, Berruezo, A., additional, Brugada, J., additional, Sitges, M., additional, Ciciarello, F. L., additional, Mandolesi, S., additional, Fedele, F., additional, Agati, L., additional, Marceca, A., additional, Rhee, S., additional, Shin, S., additional, Kim, S., additional, Yun, K., additional, Yoo, N., additional, Kim, N., additional, Oh, S., additional, Jeong, J., additional, and Alabdulkarim, N., additional
- Published
- 2011
- Full Text
- View/download PDF
11. Postsystolic shortening is a strong predictor of recovery of systolic function in patients with non-ST-elevation myocardial infarction
- Author
-
Eek, C., primary, Grenne, B., additional, Brunvand, H., additional, Aakhus, S., additional, Endresen, K., additional, Smiseth, O. A., additional, Edvardsen, T., additional, and Skulstad, H., additional
- Published
- 2011
- Full Text
- View/download PDF
12. Acute coronary occlusion in non-ST-elevation acute coronary syndrome: outcome and early identification by strain echocardiography
- Author
-
Grenne, B., primary, Eek, C., additional, Sjoli, B., additional, Dahlslett, T., additional, Uchto, M., additional, Hol, P. K., additional, Skulstad, H., additional, Smiseth, O. A., additional, Edvardsen, T., additional, and Brunvand, H., additional
- Published
- 2010
- Full Text
- View/download PDF
13. Strain echocardiography predicts acute coronary occlusion in patients with non-ST-segment elevation acute coronary syndrome
- Author
-
Eek, C., primary, Grenne, B., additional, Brunvand, H., additional, Aakhus, S., additional, Endresen, K., additional, Smiseth, O. A., additional, Edvardsen, T., additional, and Skulstad, H., additional
- Published
- 2010
- Full Text
- View/download PDF
14. Comparison of Automated Anti-Müllerian Hormone Assays and Antral Follicle Count in Predicting Ovarian Response During Ovarian Stimulation
- Author
-
Eek Chaw Tan, Pallavi Chincholkar, Su Ling Yu, Serene Liqing Lim, Rajkumaralal Renuka, Tze Tein Yong, Chin Pin Yeo, and Hemashree Rajesh
- Subjects
anti-müllerian hormone ,antral follicle count ,Reproduction ,QH471-489 - Abstract
Objective: Various parameters had been used to predict ovarian response. Among them, Anti-Müllerian Hormone (AMH) and antral follicle count (AFC) demonstrate the most favourable analytical and performance characteristics. In this pilot study, we aim to determine the cut-off levels of AMH using automated AMH assays and AFC in the prediction of poor and high responders. Study Design: Prospective study of 43 women between 21 to 45 years old scheduled for assisted reproduction. AMH levels on day 3 of menstruation were analysed using two immunoassay kits, namely the Beckman Coulter Access AMH and the Roche Elecsys AMH on the two automated analysers Beckman Coulter DxI 800 and Roche Cobas e602 respectively. AFC was also assessed on day 3 of menstruation prior to in vitro fertilization (IVF). These were compared with the number of oocytes retrieved after controlled ovarian stimulation. Results: AMH (Beckman Coulter Access AMH and Roche Elecsys AMH) highly correlated with AFC and the number of oocytes retrieved after ovarian stimulation. Beckman Coulter Access AMH was the better predictor for poor ovarian response with ROC AUC of 0.83. For the prediction of a high response, AFC had a higher ROC AUC of 0.95. Through ROC, the AMH cut-off level for poor ovarian response was 2.23 ng/ml with Beckman Coulter Access AMH and 2.02 ng/ml with Roche Elecsys AMH, while the AMH cut-off for a high ovarian response was 5.19 ng/ml with Beckman Coulter Access AMH and 4.60 ng/ml with Roche Elecsys AMH. For AFC, the cut-off for poor ovarian response was 18 and for high response was 34. Conclusion: AMH and AFC are reliable predictors of ovarian response. Establishment of specific levels may improve individualised controlled ovarian stimulation and optimise the oocyte yield. Larger studies are required to establish these findings.
- Published
- 2019
- Full Text
- View/download PDF
15. The causality field (extrinsic and intrinsic factors) in industrial subacute low back pain patients
- Author
-
Öhlund, C., primary, Lindström, I., additional, Eek, C., additional, Areskoug, B., additional, and Nachemson, A., additional
- Published
- 2007
- Full Text
- View/download PDF
16. Quantified pain drawing in subacute low back pain. Validation in a nonselected outpatient industrial sample.
- Author
-
Ohlund C, Eek C, Palmblad S, Areskoug B, Nachemson A, Ohlund, C, Eek, C, Palmbald, S, Areskoug, B, and Nachemson, A
- Published
- 1996
17. A Rare Case of Steroid Cell Tumor, Not Otherwise Specified (NOS), of the Ovary in a Young Woman
- Author
-
Eek Chaw Tan, Chit Chong Khong, and Kazila Bhutia
- Subjects
Gynecology and obstetrics ,RG1-991 - Abstract
Steroid cell tumour is a rare sex cord-stromal tumor of the ovary. It may produce steroids and is associated with testosterone secretion which causes symptoms like hair loss, hirsutism, and oligomenorrhea/amenorrhea due to hormonal activity and virilizing properties of tumor. In this article, we reported a 27-year-old woman who presented with hirsutism, hoarseness of voice, scalp hair fall, and amenorrhea for 8 years. Clinical and diagnostic evaluation revealed a left adnexal mass and elevated serum levels of testosterone and she was diagnosed as having a Sertoli Leydig cell tumour of ovary. She underwent left salpingooophorectomy and both histopathological examination and immunohistochemistry confirmed the diagnosis. Her serum testosterone levels normalized 3 days after the surgery and her menses resumed spontaneously a few months after the operation. In addition, we reviewed the literature on the epidemiology, clinical presentations, imaging and histological findings, and the treatment options on this disease.
- Published
- 2019
- Full Text
- View/download PDF
18. Pain behavior in industrial subacute low back pain. Part I. Reliability: concurrent and predictive validity of pain behavior assessments.
- Author
-
Ohlund, C, Lindström, I, Areskoug, B, Eek, C, Peterson, L E, Nachemson, A, Öhlund, Carl, Lindström, Ingalill, Areskoug, Björn, Eek, Claes, Peterson, Lars-Erik, and Nachemson, Alf
- Published
- 1994
- Full Text
- View/download PDF
19. The causality field (extrinsic and intrinsic factors) in industrial subacute low back pain patients.
- Author
-
Öhlund, C., Lindström, I., Eek, C., Areskoug, B., and Nachemson, A.
- Published
- 1996
- Full Text
- View/download PDF
20. Survival after prolonged resuscitation with 99 defibrillations due to Torsade De Pointes cardiac electrical storm: a case report
- Author
-
Larsen Anne, Aarhus Dag, Eek Christian, Nakstad Anders, and Haugaa Kristina
- Subjects
Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Abstract A 48-year-old previously healthy woman suffered witnessed cardiac arrest in hospital. She achieved return of spontaneous circulation and was transferred to the intensive care unit. During the following 3 hours, she suffered a cardiac electrical storm with 98 episodes of Torsade de Pointes ventricular tachycardia rapidly degenerating to ventricular fibrillation. She was converted with a total of 99 defibrillations. There was no response to the use of any recommended anti arrhythmic drugs. However, the use of bretylium surprisingly stabilized her heart rhythm and facilitated placing of a temporary pacemaker. Overdrive pacing prevented further arrhythmias and was life saving. A number of beneficial factors may have contributed to the good neurological outcome. Further investigations gave no explanation for her cardiac electrical storm.
- Published
- 2010
- Full Text
- View/download PDF
21. Pain behavior in industrial subacute low back pain. Part I. Reliability: concurrent and predictive validity of pain behavior assessments
- Author
-
Oehlund, C., Lindstroem, I., Areskoug, B., and Eek, C.
- Published
- 1994
- Full Text
- View/download PDF
22. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial
- Author
-
Ria van Vliet, Martijn Meuwissen, Elvin Kedhi, Vincent Roolvink, Jan C.A. Hoorntje, Stéphane Cook, Alexander Zurakowski, Marco Togni, Christian Eek, Paweł Buszman, Martin van der Ent, Hans Wedel, Carl E. Schotborgh, Ronak Delewi, Clemens von Birgelen, Felix Zijlstra, Enrico Fabris, Niels van Royen, ACS - Atherosclerosis & ischemic syndromes, ACS - Pulmonary hypertension & thrombosis, Cardiology, ACS - Microcirculation, Kedhi, E., Fabris, E., Van Der Ent, M., Buszman, P., Von Birgelen, C., Roolvink, V., Zurakowski, A., Schotborgh, C. E., Hoorntje, J. C. A., Eek, C. H., Cook, S., Togni, M., Meuwissen, M., Van Royen, N., Van Vliet, R., Wedel, H., Delewi, R., Zijlstra, F., and Health Technology & Services Research
- Subjects
Male ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Adolescent ,Adult ,Aged ,Aged, 80 and over ,Combined Modality Therapy ,Drug Administration Schedule ,Female ,Humans ,Middle Aged ,Platelet Aggregation Inhibitors ,ST Elevation Myocardial Infarction ,Sirolimus ,Treatment Outcome ,Young Adult ,Drug-Eluting Stents ,Clinical endpoint ,80 and over ,Sirolimu ,030212 general & internal medicine ,Myocardial infarction ,Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] ,General Medicine ,Thrombolysis ,Drug-eluting stent ,Human ,medicine.medical_specialty ,Ticlopidine ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,Percutaneous Coronary Intervention ,medicine ,cardiovascular diseases ,business.industry ,Platelet Aggregation Inhibitor ,Research ,Stent ,Percutaneous coronary intervention ,medicine.disease ,Surgery ,Conventional PCI ,business - Abstract
Objective To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with event-free ST-elevation myocardial infarction (STEMI) results in a non-inferior clinical outcome versus DAPT for 12 months. Design Prospective, randomised, multicentre, non-inferiority trial. Setting Patients with STEMI treated with primary percutaneous coronary intervention (PCI) and second generation zotarolimus-eluting stent. Participants Patients with STEMI aged 18 to 85 that underwent a primary PCI with the implantation of second generation drug-eluting stents were enrolled in the trial. Patients that were event-free at six months after primary PCI were randomised at this time point. Interventions Patients that were taking DAPT and were event-free at six months were randomised 1:1 to single antiplatelet therapy (SAPT) (ie, aspirin only) or to DAPT for an additional six months. All patients that were randomised were then followed for another 18 months (ie, 24 months after the primary PCI). Main outcome measures The primary endpoint was a composite of all cause mortality, any myocardial infarction, any revascularisation, stroke, and thrombolysis in myocardial infarction major bleeding at 18 months after randomisation. Results A total of 1100 patients were enrolled in the trial between 19 December 2011 and 30 June 2015. 870 were randomised: 432 to SAPT versus 438 to DAPT. The primary endpoint occurred in 4.8% of patients receiving SAPT versus 6.6% of patients receiving DAPT (hazard ratio 0.73, 95% confidence interval 0.41 to 1.27, P=0.26). Non-inferiority was met (P=0.004 for non-inferiority), as the upper 95% confidence interval of 1.27 was smaller than the prespecified non-inferiority margin of 1.66. Conclusions DAPT to six months was non-inferior to DAPT for 12 months in patients with event-free STEMI at six months after primary PCI with second generation drug-eluting stents. Trial registration Clinicaltrials.gov NCT01459627 .
- Published
- 2018
23. Long-Term Outcomes of Invasive vs Conservative Strategies for Older Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
- Author
-
Berg ES, Tegn NK, Abdelnoor M, Røysland K, Ryalen PC, Aaberge L, Eek C, Øie E, Juliebø V, Gjertsen E, Ranhoff AH, Gullestad L, Nordstrand N, and Bendz B
- Subjects
- Aged, 80 and over, Humans, Coronary Angiography methods, Treatment Outcome, Randomized Controlled Trials as Topic, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome therapy, Myocardial Infarction, Stroke
- Abstract
Background: Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is a frequent cause of hospital admission in older people, but clinical trials targeting this population are scarce., Objectives: The After Eighty Study assessed the effect of an invasive vs a conservative treatment strategy in a very old population with NSTE-ACS., Methods: Between 2010 and 2014, the investigators randomized 457 patients with NSTE-ACS aged ≥80 years (mean age 85 years) to an invasive strategy involving early coronary angiography with immediate evaluation for revascularization and optimal medical therapy or to a conservative strategy (ie, optimal medical therapy). The primary endpoint was a composite of myocardial infarction, need for urgent revascularization, stroke, and death. The long-term outcomes are presented., Results: After a median follow up of 5.3 years, the invasive strategy was superior to the conservative strategy in the reduction of the primary endpoint (incidence rate ratio: 0.76; 95% CI: 0.63-0.93; P = 0.0057). The invasive strategy demonstrated a significant gain in event-free survival of 276 days (95% CI: 151-400 days; P = 0.0001) at 5 years and 337 days (95% CI: 123-550 days; P = 0.0001) at 10 years. These results were consistent across subgroups of patients with respect to major cardiovascular prognostic factors., Conclusions: In patients aged ≥80 years with NSTE-ACS, the invasive strategy was superior to the conservative strategy in the reduction of composite events and demonstrated a significant gain in event-free survival. (The After Eighty Study: a randomized controlled trial; NCT01255540)., Competing Interests: Funding Support and Author Disclosures The After Eighty Study is an investigator-initiated study that received funding from the Norwegian Health Association (ExtraStiftelsen) and Inger and John Fredriksen Heart Foundation. Dr Tegn has received grants from the funders. The funders had no role in data collection, analysis, interpretation, writing of the manuscript or the decision to submit the report. All other authors have reported that they have no relationships relevant to the contents of this paper to declare., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions.
- Author
-
Holm NR, Andreasen LN, Neghabat O, Laanmets P, Kumsars I, Bennett J, Olsen NT, Odenstedt J, Hoffmann P, Dens J, Chowdhary S, O'Kane P, Bülow Rasmussen SH, Heigert M, Havndrup O, Van Kuijk JP, Biscaglia S, Mogensen LJH, Henareh L, Burzotta F, H Eek C, Mylotte D, Llinas MS, Koltowski L, Knaapen P, Calic S, Witt N, Santos-Pardo I, Watkins S, Lønborg J, Kristensen AT, Jensen LO, Calais F, Cockburn J, McNeice A, Kajander OA, Heestermans T, Kische S, Eftekhari A, Spratt JC, and Christiansen EH
- Subjects
- Humans, Treatment Outcome, Europe, Coronary Angiography adverse effects, Coronary Angiography methods, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Tomography, Optical Coherence adverse effects, Tomography, Optical Coherence methods
- Abstract
Background: Imaging-guided percutaneous coronary intervention (PCI) is associated with better clinical outcomes than angiography-guided PCI. Whether routine optical coherence tomography (OCT) guidance in PCI of lesions involving coronary-artery branch points (bifurcations) improves clinical outcomes as compared with angiographic guidance is uncertain., Methods: We conducted a multicenter, randomized, open-label trial at 38 centers in Europe. Patients with a clinical indication for PCI and a complex bifurcation lesion identified by means of coronary angiography were randomly assigned in a 1:1 ratio to OCT-guided PCI or angiography-guided PCI. The primary end point was a composite of major adverse cardiac events (MACE), defined as death from a cardiac cause, target-lesion myocardial infarction, or ischemia-driven target-lesion revascularization at a median follow-up of 2 years., Results: We assigned 1201 patients to OCT-guided PCI (600 patients) or angiography-guided PCI (601 patients). A total of 111 patients (18.5%) in the OCT-guided PCI group and 116 (19.3%) in the angiography-guided PCI group had a bifurcation lesion involving the left main coronary artery. At 2 years, a primary end-point event had occurred in 59 patients (10.1%) in the OCT-guided PCI group and in 83 patients (14.1%) in the angiography-guided PCI group (hazard ratio, 0.70; 95% confidence interval, 0.50 to 0.98; P = 0.035). Procedure-related complications occurred in 41 patients (6.8%) in the OCT-guided PCI group and 34 patients (5.7%) in the angiography-guided PCI group., Conclusions: Among patients with complex coronary-artery bifurcation lesions, OCT-guided PCI was associated with a lower incidence of MACE at 2 years than angiography-guided PCI. (Funded by Abbott Vascular and others; OCTOBER ClinicalTrials.gov number, NCT03171311.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
25. Guideline-Recommended Time Less Than 90 Minutes From ECG to Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Is Associated with Major Survival Benefits, Especially in Octogenarians: A Contemporary Report in 11 226 Patients from NORIC.
- Author
-
Larsen AI, Løland KH, Hovland S, Bleie Ø, Eek C, Fossum E, Trovik T, Juliebø V, Hegbom K, Moer R, Larsen T, Uchto M, and Rotevatn S
- Subjects
- Aged, Aged, 80 and over, Electrocardiography, Humans, Octogenarians, Risk Factors, Time Factors, Treatment Outcome, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction surgery
- Abstract
Background Using contemporary data from NORIC (Norwegian Registry of Invasive Cardiology) we investigated the predictive value of patient age and time from ECG diagnosis to sheath insertion (ECG-2-sheath) in primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction (STEMI). Methods and Results Data from 11 226 patients collected from all centers offering 24/7/365 primary percutaneous coronary intervention service were explored. For patients aged <80 years the mortality rates were 5.6% and 7.6% at 30 days and 1 year, respectively. For octogenarians the corresponding rates were 15.0% and 24.2%. The Cox hazard ratio was 2.02 (1.93-2.11, P value <0.0001) per 10 years of patient age. Time from ECG-2-sheath was significantly associated with mortality with a 3.6% increase per 30 minutes of time. Using achievement of time goal <90 minutes in patients aged >80 years and mortality at 30 days, mortality was 10.5% and 17.7% for <90 or ≥90 minutes, respectively. The number needed to prevent 1 death was 39 in the whole population and 14 in the elderly. Restricted mean survival gains during median 938 days of follow-up in patients with ECG-2-sheath time <90 minutes were 24 and 76 days for patients aged <80 and ≥80 years, respectively. Conclusions Time from ECG-diagnosis to sheath insertion is strongly correlated with mortality. This applies especially to octogenarians who derive the most in terms of absolute mortality reduction. Registration URL: https://helsedata.no/en/forvaltere/norwegian-institute-of-public-health/norwegian-registry-of-invasive-cardiology/.
- Published
- 2022
- Full Text
- View/download PDF
26. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
- Author
-
Hestvik ALK, Frederiksen JL, Nielsen HH, Torkildsen Ø, Eek C, Huang-Link Y, Haghighi S, Tsai JA, and Kant M
- Subjects
- Crotonates adverse effects, Fatigue drug therapy, Humans, Hydroxybutyrates, Nitriles, Prospective Studies, Quality of Life, Recurrence, Toluidines adverse effects, Multiple Sclerosis drug therapy, Multiple Sclerosis, Relapsing-Remitting chemically induced, Multiple Sclerosis, Relapsing-Remitting drug therapy
- Abstract
Background: Teriflunomide 14 mg (Aubagio®) is a once-daily, oral drug approved for the treatment of relapsing forms of multiple sclerosis (MS). While the efficacy and safety of teriflunomide have been thoroughly characterised across an extensive clinical program, we were interested in studying performance of the drug with respect to quality-of-life (QoL) outcomes in persons with MS in a real-world setting., Methods: Teri-LIFE was a prospective, open label, non-interventional, observational, multi-centre study that enrolled 200 teriflunomide-treated patients from three Nordic countries. The primary outcome measure changes in patient-reported QoL over 24 months as measured by the Short Form-36 (SF-36) questionnaire. Secondary endpoints included clinical efficacy, fatigue, safety, treatment satisfaction (Treatment Satisfaction Questionnaire for Medication version 1.4 (TSQM-1.4)), treatment adherence, and health economic outcomes. Most assessments were made at baseline and then at 6-monthly intervals., Results: Overall, changes in SF-36 scores from baseline to last visit indicated a stable QoL during treatment with teriflunomide for up to 24 months. Relapse activity decreased during the study compared to the pre-baseline period (p<0.001), patient-reported disability increased marginally, and no substantial change was seen in fatigue scores. The mean scores for TSQM domains increased nominally though not significantly from Month 6 to Month 24. The convenience and side effects TSQM domains recorded the highest median scores, indicating the acceptability of oral teriflunomide in this cohort. This was reflected in a generally high treatment adherence and decreased healthcare utilization during the study period. Some differences were seen between treatment-naïve and previously treated patients, likely reflecting different patient demographics and disease status at study entry, along with different treatment expectations., Conclusion: Teri-LIFE offers a reliable snapshot of QoL, efficacy, safety, and health economic outcomes in persons with relapsing MS treated with teriflunomide in routine clinical practice in Nordic countries The results were consistent with previous clinical trials and real-world studies., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
27. Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study.
- Author
-
Tegn N, Eek C, Abdelnoor M, Aaberge L, Endresen K, Skårdal R, Berg ES, Gullestad L, and Bendz B
- Subjects
- Age Factors, Aged, 80 and over, Angina, Unstable diagnostic imaging, Angina, Unstable mortality, Bundle-Branch Block, Drug-Eluting Stents, Female, Humans, Male, Norway, Predictive Value of Tests, Prospective Studies, Risk Assessment, Risk Factors, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction mortality, Sex Factors, Smoking adverse effects, Time Factors, Treatment Outcome, Angina, Unstable therapy, Conservative Treatment adverse effects, Conservative Treatment mortality, Coronary Angiography, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Percutaneous Coronary Intervention mortality, ST Elevation Myocardial Infarction therapy
- Abstract
Objectives: We aimed to report the angiographic and procedural results of the After Eighty study (ClinicalTrials.gov, NCT01255540), and to identify independent predictors of revascularisation., Methods: Patients of ≥80 years old with non-ST-elevation myocardial infarction and unstable angina pectoris were randomised to an invasive or conservative strategy. Angiographic and procedural results were recorded. Univariate and multivariate analyses were performed to explore variables predicting revascularisation., Results: Among 229 patients in the invasive group, 220 underwent immediate coronary angiography (90% performed via the radial artery). Of these patients, 48% had three-vessel disease or left main stenosis, 18% two-vessel disease, 16% one-vessel disease, 17% minor coronary vessel wall changes and two patients had normal coronary arteries. Six patients (3%) underwent coronary artery bypass graft. Percutaneous coronary intervention (PCI) was performed in 107 patients (49%), with 57% treated with bare metal stents, 37% drug-eluting stents and 6% balloon angioplasty. On average, 1.7 lesions were treated and 2 stents delivered per patient. Complications included 1 major PCI-related bleeding (successfully treated), 2 minor access site-related bleedings, 3 side branch occlusions during PCI and 11 periprocedural myocardial infarctions (considered end points). Sex, bundle branch block and smoking were independent predictors of revascularisation., Conclusions: PCI was performed in approximately half of the patients, similar to findings in younger populations. Procedural success was high, with few complications., Trial Registration Number: NCT01255540., Competing Interests: Competing interests: The authors declare that the paper is not under consideration elsewhere, that none of the paper’s contents have been published previously, and that all authors have read and approved the manuscript. The authors have no potential conflict of interest., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
28. Mechanical dispersion as a marker of left ventricular dysfunction and prognosis in stable coronary artery disease.
- Author
-
Kvisvik B, Aagaard EN, Mørkrid L, Røsjø H, Lyngbakken M, Smedsrud MK, Eek C, Bendz B, Haugaa KH, Edvardsen T, and Gravning J
- Subjects
- Aged, Biomarkers blood, Cause of Death, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Coronary Artery Disease physiopathology, Female, Humans, Male, Middle Aged, Natriuretic Peptide, Brain blood, Patient Readmission, Peptide Fragments blood, Predictive Value of Tests, Prospective Studies, Risk Factors, Time Factors, Treatment Outcome, Troponin I blood, Ventricular Dysfunction, Left mortality, Ventricular Dysfunction, Left physiopathology, Ventricular Dysfunction, Left therapy, Coronary Artery Disease surgery, Echocardiography, Myocardial Revascularization adverse effects, Myocardial Revascularization mortality, Ventricular Dysfunction, Left diagnostic imaging, Ventricular Function, Left
- Abstract
Assessment of global longitudinal strain (GLS) is superior to ejection fraction (EF) in the evaluation of left ventricular (LV) function in patients with stable coronary artery disease (CAD). However, the role of mechanical dispersion (MD) in this context remains unresolved. We aimed to evaluate the potential role of MD as a marker of LV dysfunction and long-term prognosis in stable CAD. EF, GLS and MD were assessed in 160 patients with stable CAD, 1 year after successful coronary revascularization. Serum levels of high-sensitivity cardiac troponin I (hs-cTnI) and amino-terminal pro B-type natriuretic peptide (NT-proBNP) were quantified as surrogate markers of LV dysfunction. The primary endpoint was defined as all-cause mortality, the secondary endpoint was defined as the composite of all-cause mortality and hospitalization for acute myocardial infarction or heart failure during follow-up. Whereas no associations between EF and the biochemical markers of LV function were found, both GLS and MD correlated positively with increasing levels of hs-cTnI (R = 0.315, P < 0.001 and R = 0.442, P < 0.001, respectively) and NT-proBNP (R = 0.195, P = 0.016 and R = 0.390, P < 0.001, respectively). Median MD was 46 ms (interquartile range [IQR] 37-53) and was successfully quantified in 96% of the patients. During a median follow-up of 8.4 (IQR 8.2-8.8) years, 14 deaths and 29 secondary events occurred. MD was significantly increased in non-survivors, and provided incremental prognostic value when added to EF and GLS. NT-proBNP was superior to the echocardiographic markers in predicting adverse outcomes. MD may be a promising marker of LV dysfunction and adverse prognosis in stable CAD.
- Published
- 2019
- Full Text
- View/download PDF
29. Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER).
- Author
-
Holm NR, Andreasen LN, Walsh S, Kajander OA, Witt N, Eek C, Knaapen P, Koltowski L, Gutiérrez-Chico JL, Burzotta F, Kockman J, Ormiston J, Santos-Pardo I, Laanmets P, Mylotte D, Madsen M, Hjort J, Kumsars I, Råmunddal T, and Christiansen EH
- Subjects
- Aged, Coronary Angiography, Coronary Stenosis surgery, Female, Humans, Male, Middle Aged, Treatment Outcome, Coronary Stenosis diagnosis, Coronary Vessels diagnostic imaging, Drug-Eluting Stents, Percutaneous Coronary Intervention methods, Tomography, Optical Coherence methods
- Abstract
Background: Percutaneous coronary intervention in complex bifurcation lesions is prone to suboptimal implantation results and is associated with increased risk of subsequent clinical events. Angiographic ambiguity is high during bifurcation stenting, but it is unknown if procedural guidance by intravascular optical coherence tomography (OCT) improves clinical outcome., Methods and Design: OCTOBER is a randomized, investigator-initiated, multicenter trial aimed to show superiority of OCT-guided stent implantation compared to standard angiographic-guided implantation in bifurcation lesions. The primary outcome measure is a 2-year composite end point of cardiac death, target lesion myocardial infarction, and ischemia-driven target lesion revascularization. The calculated sample size is 1,200 patients in total, and allocation is 1:1. Eligible patients have stable or unstable angina pectoris or stabilized non–ST elevation myocardial infarction, and a coronary bifurcation lesion with significant main vessel stenosis and more than 50 % stenosis in a side branch with a reference diameter ≥2.5mm. Treatment is performed by the provisional side branch stenting technique or 2-stent techniques, and the systematic OCT guiding protocol is aimed to evaluate (1) plaque preparation, (2) lesion length, (3) segmental reference sizes, (4) lesion coverage, (5) stent expansion, (6) malapposition, (7) wire positions, and (8) ostial results., Implications: A positive outcome of the OCTOBER trial may establish OCT as a routine tool for optimization of complex percutaneous coronary intervention, whereas a negative result would indicate that OCT remains a tool for ad hoc evaluation in selected cases., (© 2018 The Authors. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
30. Akutt hjerteinfarkt uten ST-elevasjon - kan pasientene vente?
- Author
-
Eek C, Jortveit J, and Jakobsen OJ
- Published
- 2018
- Full Text
- View/download PDF
31. High-Sensitivity Troponin T vs I in Acute Coronary Syndrome: Prediction of Significant Coronary Lesions and Long-term Prognosis.
- Author
-
Kvisvik B, Mørkrid L, Røsjø H, Cvancarova M, Rowe AD, Eek C, Bendz B, Edvardsen T, and Gravning J
- Subjects
- Aged, Coronary Angiography, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Acute Coronary Syndrome blood, Acute Coronary Syndrome diagnosis, Coronary Artery Disease blood, Coronary Artery Disease diagnosis, Troponin I blood, Troponin T blood
- Abstract
Background: High-sensitivity cardiac troponin (hs-cTn) T and I assays are established as crucial tools for the diagnosis of acute myocardial infarction (AMI), as they have been found superior to old troponin assays. However, eventual differences between the assays in prediction of significant coronary lesions and long-term prognosis in patients with acute coronary syndrome (ACS) have not been fully unraveled., Methods: Serum concentrations of hs-cTnT (Roche), hs-cTnI (Abbott), and amino-terminal pro-B-type natriuretic peptide (NT-proBNP; Roche) in 390 non-ST-elevation (NSTE) ACS patients were evaluated in relation to significant coronary lesions on coronary angiography (defined as a stenosis >50% of the luminal diameter, with need for revascularization) and prognostic accuracy for cardiovascular mortality, all-cause mortality, as well as the composite end point of cardiovascular mortality and hospitalizations for AMI or heart failure., Results: The mean (SD) follow-up was 2921 (168) days. Absolute hs-cTnI concentrations were significantly higher than the hs-cTnT concentrations. The relationship between analyzed biomarkers and significant coronary lesions on coronary angiography, as quantified by the area under the ROC curve (AUC), revealed no difference between hs-cTnT [AUC, 0.81; 95% CI, 0.77-0.86] and hs-cTnI (AUC, 0.81; 95% CI, 0.76-0.86; P = NS). NT-proBNP was superior to both hs-cTn assays regarding prognostic accuracy for both cardiovascular and all-cause mortality and for the composite end point during follow-up, also in multivariate analyses., Conclusions: The hs-cTnT and hs-cTnI assays displayed a similar ability to predict significant coronary lesions in NSTE-ACS patients. NT-proBNP was superior to both hs-cTn assays as a marker of long-term prognosis in this patient group., (© 2016 American Association for Clinical Chemistry.)
- Published
- 2017
- Full Text
- View/download PDF
32. Non-invasive myocardial work index identifies acute coronary occlusion in patients with non-ST-segment elevation-acute coronary syndrome.
- Author
-
Boe E, Russell K, Eek C, Eriksen M, Remme EW, Smiseth OA, and Skulstad H
- Subjects
- Acute Coronary Syndrome physiopathology, Coronary Angiography, Coronary Occlusion physiopathology, Female, Humans, Male, Middle Aged, Risk Assessment, Risk Factors, Sensitivity and Specificity, Ultrasonography, Acute Coronary Syndrome complications, Acute Coronary Syndrome diagnostic imaging, Coronary Occlusion diagnostic imaging, Coronary Occlusion etiology
- Abstract
Aims: Acute coronary artery occlusion (ACO) occurs in ∼30% of patients with non-ST-segment elevation-acute coronary syndrome (NSTE-ACS). We investigated the ability of a regional non-invasive myocardial work index (MWI) to identify ACO., Methods and Results: Segmental strain analysis was performed before coronary angiography in 126 patients with NSTE-ACS. Left ventricular (LV) pressure was estimated non-invasively using a standard waveform fitted to valvular events and scaled to systolic blood pressure. MWI was calculated as the area of the LV pressure-strain loop. Empirical cut-off values were set to identify segmental systolic dysfunction for MWI (<1700 mmHg %) and strain (more than -14%). The number of dysfunctional segments was used in ROC analysis to identify ACO. The presence of ≥4 adjacent dysfunctional segments assessed by MWI was significantly better than both global strain and ejection fraction at detecting the occurrence of ACO (P < 0.05). Regional MWI had a higher sensitivity (81 vs. 78%) and especially specificity (82 vs. 65%) compared with regional strain. Logistic regression demonstrated that elevated systolic blood pressure significantly decreased the probability of actual ACO in a patient with an area of impaired regional strain., Conclusion: The presence of a region of reduced MWI in patients with NSTE-ACS identified patients with ACO and was superior to all other parameters. The regional MWI was able to account for the influence of systolic blood pressure on regional contraction. We therefore propose that MWI may serve as an important clinical tool for selecting patients in need of prompt invasive treatment., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
33. Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain.
- Author
-
Smedsrud MK, Gravning J, Omland T, Eek C, Mørkrid L, Skulstad H, Aaberge L, Bendz B, Kjekshus J, and Edvardsen T
- Subjects
- Aged, Biomarkers blood, Biomechanical Phenomena, Coronary Angiography, Coronary Artery Disease blood, Coronary Artery Disease physiopathology, Coronary Artery Disease therapy, Echocardiography, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Myocardial Infarction blood, Myocardial Infarction physiopathology, Myocardial Infarction therapy, Myocardial Revascularization, Myocardium pathology, Necrosis, Norway, Predictive Value of Tests, Prospective Studies, Stress, Mechanical, Time Factors, Treatment Outcome, Ventricular Remodeling, Coronary Artery Disease diagnosis, Myocardial Contraction, Myocardial Infarction diagnosis, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Troponin I blood, Troponin T blood, Ventricular Function, Left
- Abstract
N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponins (cTns) measured with sensitive assays provide strong prognostic information in patients with stable coronary artery disease. However, the relationship between these biomarkers and myocardial contractile function, as well as infarct size, in this patient group, remains to be defined. The study population consisted of 160 patients referred to a follow-up echocardiography scheduled 1 year after coronary revascularization. Concentrations of NT-proBNP, high-sensitive cTnT (hs-cTnT) and sensitive cTnI assays were assessed. Left ventricular function was measured as global peak systolic longitudinal strain by speckle tracking echocardiography and infarct size was assessed by late-enhancement MRI. NT-proBNP and sensitive cTnI levels were significantly associated with left ventricular function by peak systolic strain (R-values 0.243 and 0.228, p = 0.002 and 0.004) as well as infarct size (R-values 0.343 and 0.366, p = 0.014 and p = 0.008). In contrast, hs-cTnT did not correlate with left ventricular function (R = 0.095, p = 0.231) and only marginally with infarct size (R = 0.237, p = 0.094). NT-proBNP and sensitive cTnI levels correlate with left ventricular function and infarct size in patients with stable coronary artery disease after revascularization. As opposed to hs-cTnT, NT-proBNP and cTnI seem to be indicators of incipient myocardial dysfunction and the extent of myocardial necrosis.
- Published
- 2015
- Full Text
- View/download PDF
34. Early assessment of strain echocardiography can accurately exclude significant coronary artery stenosis in suspected non-ST-segment elevation acute coronary syndrome.
- Author
-
Dahlslett T, Karlsen S, Grenne B, Eek C, Sjøli B, Skulstad H, Smiseth OA, Edvardsen T, and Brunvand H
- Subjects
- Acute Coronary Syndrome complications, Coronary Stenosis complications, Diagnosis, Differential, Early Diagnosis, Female, Humans, Male, Middle Aged, Reproducibility of Results, Sensitivity and Specificity, Ventricular Dysfunction, Left etiology, Acute Coronary Syndrome diagnostic imaging, Coronary Stenosis diagnostic imaging, Echocardiography methods, Elasticity Imaging Techniques methods, Image Interpretation, Computer-Assisted methods, Ventricular Dysfunction, Left diagnostic imaging
- Abstract
Background: Many patients with suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) do not have significant coronary artery disease. The current diagnostic approach of repeated electrocardiography and cardiac biomarker assessment requires observation for >6 to 12 hours. This strategy places a heavy burden on hospital facilities. The objective of this study was to investigate whether myocardial strain assessment by echocardiography could exclude significant coronary artery stenosis in patients presenting with suspected NSTE-ACS., Methods: Sixty-four patients presenting to the emergency department with suspected NSTE-ACS without known coronary artery disease, inconclusive electrocardiographic findings, and normal cardiac biomarkers at arrival were enrolled. Twelve-lead electrocardiography, troponin T assay, and echocardiography were performed at arrival, and all patients underwent coronary angiography. Significant coronary stenosis was defined as >50% luminal narrowing. Global myocardial peak systolic longitudinal strain was measured using speckle-tracking echocardiography. Left ventricular ejection fraction and wall motion score index were calculated., Results: No significant stenosis in any coronary artery was found in 35 patients (55%). Global peak systolic longitudinal strain was superior to conventional echocardiographic parameters in distinguishing patients with and without significant coronary artery stenosis (area under the curve, 0.87). Sensitivity and specificity were calculated as 0.93 and 0.78, respectively, and positive predictive value and negative predictive value as 0.74 and 0.92, respectively. Feasibility of the strain measurements was excellent, with 97% of segments analyzed., Conclusions: Myocardial strain by echocardiography may facilitate the exclusion of significant coronary artery stenosis among patients presenting with suspected NSTE-ACS with inconclusive electrocardiographic findings and normal cardiac biomarkers., (Copyright © 2014 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
35. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction.
- Author
-
Gullestad L, Orn S, Dickstein K, Eek C, Edvardsen T, Aakhus S, Askevold ET, Michelsen A, Bendz B, Skårdal R, Smith HJ, Yndestad A, Ueland T, and Aukrust P
- Subjects
- Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction diagnosis, Myocardial Infarction physiopathology, Ventricular Function, Left physiology, Ventricular Remodeling physiology, Hospitalization trends, Immunoglobulins, Intravenous administration & dosage, Myocardial Infarction drug therapy, Ventricular Function, Left drug effects, Ventricular Remodeling drug effects
- Abstract
Background: Left ventricular (LV) remodeling takes place after acute myocardial infarction (MI), potentially leading to overt heart failure (HF). Enhanced inflammation may contribute to LV remodeling. Our hypothesis was that the immunomodulating effects of intravenous immunoglobulin (IVIg) would be beneficial in patients with impaired myocardial function after MI by reducing myocardial remodeling and improving myocardial function., Methods: Sixty-two patients with acute MI treated by percutaneous coronary intervention, with depressed LV ejection fraction (LVEF) were randomized in a double-blinded fashion to IVIg as induction therapy and thereafter as monthly infusions or placebo for 26 weeks. The primary end point was changes in LVEF from baseline to 6 months as assessed by MRI., Results: Our main findings were: (i) LVEF increased significantly from 38 ± 10 (mean ± SD) to 45 ± 13% after IVIg and from 42 ± 9 to 49 ± 12% after placebo with no difference between the groups. (ii) The scar area decreased significantly by 3% and 5% in the IVIg and placebo group, respectively, with no difference between the groups. (iii) During the induction therapy (baseline to day 5), IVIg induced both inflammatory (e.g., increase in tumor necrosis factor α and monocyte chemoattractant protein-1) and anti-inflammatory (e.g., increase in interleukin-10 and decrease in leukocyte counts) variables, but during maintenance therapy there were no differences in changes of inflammatory mediators between IVIg and placebo., Conclusions: IVIg therapy after ST elevation MI managed by primary PCI does not affect LV remodeling or function. This illustrates the challenges of therapeutic intervention directed against the cytokine network, to prevent post-MI remodeling., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
36. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis.
- Author
-
Gravning J, Smedsrud MK, Omland T, Eek C, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Mørkrid L, and Edvardsen T
- Subjects
- Acute Coronary Syndrome diagnosis, Aged, Biomarkers blood, Coronary Angiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Protein Precursors, ROC Curve, Time Factors, Acute Coronary Syndrome blood, Early Diagnosis, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Troponin I blood, Troponin T blood
- Abstract
Background: Sensitive troponin assays have substantially improved early diagnosis of myocardial infarction. However, the role of sensitive cardiac troponin (cTn) assays in prediction of significant coronary lesions and long-term prognosis in non-ST-elevation acute coronary syndrome (NSTE-ACS) remains unresolved., Methods: This prospective study includes 458 consecutive patients with NSTE-ACS admitted for coronary angiography. Serum levels of 4 commercial available sensitive troponin assays were analyzed (Roche high-sensitive cTnT [hs-cTnT; Roche Diagnostics, Basel, Switzerland], Siemens cTnI Ultra [Siemens, Munich, Germany], Abbott-Architect cTnI [Abbott, Abbott Park, IL], Access Accu-cTnI [Beckman Coulter, Nyon, Switzerland]), as well as a standard assay (Roche cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), before coronary angiography., Results: The relationship between the analyzed biomarkers and significant coronary lesions on coronary angiography, as quantified by area under the receiver operating characteristic curve, was significantly higher with Roche hs-cTnT, Siemens cTnI Ultra, and Access Accu-cTnI as compared with standard troponin T assay (P < .001 for all comparisons). This difference was mainly caused by increased sensitivity below the 99th percentile. Also, NT-proBNP was associated with the presence of significant coronary lesions. Cardiac troponin values were correlated with cardiac death (primary end point) during 1373 (1257-1478) days of follow-up. In both univariate and multivariate Cox regression analyses, NT-proBNP was superior to both hs-cTnT and cTnI in prediction of cardiovascular mortality. Troponin values with all assays were correlated with the need for repeated revascularization (secondary end point) during follow-up., Conclusions: Sensitive cTn assays are superior to standard cTnT assay in prediction of significant coronary lesions in patients with NSTE-ACS. However, this improvement is primary caused by increased sensitivity below the 99th percentile. N-terminal pro-B-type natriuretic peptide is superior to cTns in prediction of long-term mortality., (Copyright © 2013 Mosby, Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
37. NT-proBNP predicts myocardial recovery after non-ST-elevation acute coronary syndrome.
- Author
-
Broch K, Eek C, Wergeland R, Ueland T, Skårdal R, Aukrust P, Skulstad H, and Gullestad L
- Subjects
- Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome pathology, Biomarkers, Coronary Angiography, Female, Heart Ventricles, Humans, Linear Models, Magnetic Resonance Imaging, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Prognosis, Prospective Studies, Statistics as Topic, Treatment Outcome, Ultrasonography, Acute Coronary Syndrome blood, C-Reactive Protein, Myocardium, Natriuretic Peptide, Brain, Peptide Fragments, Troponin T
- Abstract
Objectives: Our aim was to investigate the associations between B-type natriuretic peptide (NT-proBNP), troponin T (TnT) and C-reactive protein (CRP) and changes in left ventricular function and size after acute coronary syndrome., Design: In 119 patients admitted for non-ST-elevation acute coronary syndrome, echocardiography and blood sampling were performed prior to coronary angiography. Echocardiography was repeated at follow-up after 8 ± 3 months. Left ventricular function was assessed by speckle tracking echocardiography. In 50 patients, infarct size was determined by magnetic resonance imaging. The associations between baseline levels of NT-proBNP, TnT and CRP and myocardial functional recovery, left ventricular intraventricular volumes and infarct size were determined by linear regression., Results: All three biomarkers were associated with myocardial dysfunction at baseline. However, high levels of NT-proBNP were associated with better myocardial recovery, as measured by global longitudinal strain, even after adjusting for other factors potentially influencing myocardial recovery., Conclusion: Elevated levels of NT-proBNP at baseline are independently associated with improved myocardial performance 8 months after non-ST-elevation acute coronary syndrome.
- Published
- 2012
- Full Text
- View/download PDF
38. Mean strain throughout the heart cycle by longitudinal two-dimensional speckle-tracking echocardiography enables early prediction of infarct size.
- Author
-
Grenne B, Eek C, Sjøli B, Dahlslett T, Hol PK, Orn S, Skulstad H, Smiseth OA, Edvardsen T, and Brunvand H
- Subjects
- Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction physiopathology, Myocardial Infarction surgery, Myocardial Revascularization, Predictive Value of Tests, Prognosis, Severity of Illness Index, Echocardiography methods, Heart Rate, Myocardial Contraction physiology, Myocardial Infarction diagnostic imaging, Stroke Volume physiology
- Abstract
Background: Early prediction of infarct size directs therapy in patients with acute myocardial infarction (AMI). Global strain by echocardiography describes myocardial deformation and correlates with infarct size. However, peak strain measures deformation at a single time point, whereas ischemia and necrosis influence deformation throughout the heart cycle. It was hypothesized that the measurement of myocardial deformation throughout the heart cycle by mean strain is a more comprehensive expression of myocardial deformation. The aim of this study was to assess the ability of mean strain to predict infarct size and to identify large infarctions at admission and after revascularization in patients with AMI., Methods: Seventy-six patients with AMI were included. Echocardiographic measurements were performed at admission and after revascularization. Myocardial strain was calculated using speckle-tracking echocardiography. Infarct size was measured using contrast-enhanced magnetic resonance imaging ≥3 months after revascularization., Results: There were significant correlations between infarct size and longitudinal global mean strain, longitudinal global strain, and left ventricular ejection fraction (P < .0001), both at admission and after revascularization. The correlations improved after revascularization. Longitudinal global mean strain had the best correlation with infarct size and the best ability to discriminate between different infarct size categories. At admission, a cutoff value of -7.6 had 89% sensitivity, 88% specificity, and an area under the receiver operating characteristic curve of 0.92 for the identification of large infarctions. Prediction of infarct size improved for all parameters after revascularization., Conclusions: Longitudinal global mean strain provides improved early prediction of infarct size in patients with AMI compared with longitudinal global strain and left ventricular ejection fraction.
- Published
- 2011
- Full Text
- View/download PDF
39. Changes of myocardial function in patients with non-ST-elevation acute coronary syndrome awaiting coronary angiography.
- Author
-
Grenne B, Eek C, Sjøli B, Skulstad H, Aakhus S, Smiseth OA, Edvardsen T, and Brunvand H
- Subjects
- Acute Coronary Syndrome diagnosis, Aged, Diagnosis, Differential, Echocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Observer Variation, Reproducibility of Results, Severity of Illness Index, Time Factors, Acute Coronary Syndrome physiopathology, Coronary Angiography, Electrocardiography, Myocardial Contraction physiology
- Abstract
The optimal timing of coronary angiography in patients with non-ST elevation (NSTE) acute coronary syndromes (ACS) is debated. American Heart Association and American College of Cardiology guidelines recommend an early invasive strategy <12 to 48 hours after the onset of symptoms. The objective of the present study was to determine possible changes in myocardial function in patients with NSTE ACS awaiting coronary angiography. One hundred two patients with suspected NSTE ACS were enrolled, including 56 with NSTE myocardial infarctions (NSTEMIs), 23 with unstable angina pectoris, and 23 with noncoronary chest pain. Global and regional myocardial function was measured as longitudinal and circumferential strain using speckle-tracking echocardiography. Measurements were performed at admission and immediately before coronary angiography (30 + or - 16 hours after admission). In patients with NSTEMIs, there was deterioration in longitudinal global strain from -16.1 + or - 2.6% at admission to -15.0 + or - 2.6% before coronary angiography (p <0.001). This was due to deterioration in longitudinal strain in the territory supplied by the infarct-related artery from -14.2 + or - 4.2% to -12.0 + or - 4.1% (p <0.001). Patients with NSTEMIs due to acute coronary occlusion underwent prominent worsening in longitudinal and circumferential strains (-15.7 + or - 2.9% to -13.9 + or - 3.0%, p = 0.001, and -16.7 + or - 4.0% to -15.0 + or - 3.9%, p = 0.01, respectively) compared to patients with NSTEMIs without occlusions. There were no changes in strain in patients with unstable angina pectoris or noncoronary chest pain. In patients with NSTEMIs without acute coronary occlusions, myocardial function improved after revascularization, whereas patients with acute occlusions demonstrated no improvement. In conclusion, myocardial function deteriorates in patients with NSTEMIs awaiting coronary angiography. Patients with acute coronary occlusions have the most prominent deterioration, and this subgroup shows no recovery of function after revascularization., (Copyright 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
40. Strain echocardiography and wall motion score index predicts final infarct size in patients with non-ST-segment-elevation myocardial infarction.
- Author
-
Eek C, Grenne B, Brunvand H, Aakhus S, Endresen K, Hol PK, Smith HJ, Smiseth OA, Edvardsen T, and Skulstad H
- Subjects
- Chi-Square Distribution, Coronary Angiography, Female, Humans, Male, Middle Aged, Myocardial Infarction drug therapy, Predictive Value of Tests, Prospective Studies, ROC Curve, Regression Analysis, Reproducibility of Results, Risk Factors, Systole, Echocardiography, Stress methods, Myocardial Infarction diagnostic imaging, Myocardial Infarction physiopathology
- Abstract
Background: Infarct size is a strong predictor of mortality and major adverse cardiovascular events after myocardial infarction. Acute reperfusion therapy limits infarct size and improves survival, but its use has been confined to patients with ST-segment-elevation myocardial infarction. The purpose of this study was to assess the relationship between echocardiographic parameters of left ventricular (LV) systolic function obtained before revascularization and final infarct size in patients with non-ST-segment-elevation myocardial infarction, as well as the ability of these parameters to identify patients with substantial infarction., Methods and Results: Sixty-one patients with non-ST-segment-elevation myocardial infarction were examined by echocardiography immediately before revascularization, 2.1+/-0.6 days after hospitalization. LV systolic function was assessed by ejection fraction, wall motion score index, and circumferential, longitudinal, and radial strain in a 16-segment LV model. Global strain represents average segmental strain values. Infarct size was assessed after 9+/-3 months by late-enhancement MRI, as a percentage of total LV myocardial volume. A good correlation was found between infarct size and wall motion score index (r=0.74, P<0.001) and global longitudinal strain (r=0.68, P<0.001). Global longitudinal strain >-13.8% and wall motion score index >1.30 accurately identified patients with substantial infarction (> or =12% of myocardium, n=13; area under the receiver operator curve, 0.95 and 0.92, respectively)., Conclusions: Echocardiographic parameters of LV systolic function correlate to infarct size in patients with non-ST-segment-elevation myocardial infarction. Global longitudinal strain and wall motion score index are both excellent parameters to identify patients with substantial myocardial infarction, who may benefit from urgent reperfusion therapy.
- Published
- 2010
- Full Text
- View/download PDF
41. Survival after prolonged resuscitation with 99 defibrillations due to Torsade De Pointes cardiac electrical storm: a case report.
- Author
-
Nakstad AR, Eek C, Aarhus D, Larsen A, and Haugaa KH
- Subjects
- Anti-Arrhythmia Agents therapeutic use, Bretylium Compounds therapeutic use, Female, Heart Arrest complications, Humans, Intensive Care Units, Middle Aged, Torsades de Pointes etiology, Torsades de Pointes therapy, Ventricular Fibrillation diagnosis, Ventricular Fibrillation etiology, Ventricular Fibrillation therapy, Cardiopulmonary Resuscitation methods, Heart Arrest therapy, Seizures complications, Torsades de Pointes complications
- Abstract
A 48-year-old previously healthy woman suffered witnessed cardiac arrest in hospital. She achieved return of spontaneous circulation and was transferred to the intensive care unit. During the following 3 hours, she suffered a cardiac electrical storm with 98 episodes of Torsade de Pointes ventricular tachycardia rapidly degenerating to ventricular fibrillation. She was converted with a total of 99 defibrillations. There was no response to the use of any recommended anti arrhythmic drugs. However, the use of bretylium surprisingly stabilized her heart rhythm and facilitated placing of a temporary pacemaker. Overdrive pacing prevented further arrhythmias and was life saving. A number of beneficial factors may have contributed to the good neurological outcome. Further investigations gave no explanation for her cardiac electrical storm.
- Published
- 2010
- Full Text
- View/download PDF
42. Mobility, strength, and fitness after a graded activity program for patients with subacute low back pain. A randomized prospective clinical study with a behavioral therapy approach.
- Author
-
Lindström I, Ohlund C, Eek C, Wallin L, Peterson LE, and Nachemson A
- Subjects
- Back Pain epidemiology, Disability Evaluation, Female, Follow-Up Studies, Humans, Male, Physical Examination, Physical Fitness, Physical Therapy Modalities, Work Capacity Evaluation, Back Pain rehabilitation, Behavior Therapy
- Abstract
Patients with nonspecific mechanical low back pain (n = 103), examined by an orthopaedic surgeon and a social worker, were randomized to an activity group (n = 51) and a control group (n = 52). Patients with defined orthopaedic, medical, or psychiatric diagnoses were excluded before randomization. No patients were excluded due to place of birth or difficulties in speaking or understanding the Swedish language. The purpose of the study was to compare mobility, strength and fitness after traditional care and after traditional care plus a graded activity program with a behavioral therapy approach. A graded activity program, with a behavioral therapy approach was given under the guidance of a physical therapist. The endpoint of the graded activity program was return to work. This program significantly increased mobility, strength, and fitness more than could be explained by only a time recovery effect, especially in males. The patients in the activity group returned to work earlier than did the patients in the control group. Spinal rotation, abdominal muscle endurance time and lifting capacity were significantly correlated to rate of return to work. Traditional care plus a graded activity program were superior to only traditional care, evaluated in terms of mobility, strength and fitness. The graded activity program proved to be a successful method of restoring occupational function and facilitating return to work in subacute low back pain patients. The patients in the graded activity program learned that it is safe to move, while regaining function.
- Published
- 1992
- Full Text
- View/download PDF
43. The effect of graded activity on patients with subacute low back pain: a randomized prospective clinical study with an operant-conditioning behavioral approach.
- Author
-
Lindström I, Ohlund C, Eek C, Wallin L, Peterson LE, Fordyce WE, and Nachemson AL
- Subjects
- Absenteeism, Adult, Back Pain diagnosis, Back Pain etiology, Behavior Therapy methods, Combined Modality Therapy, Exercise Therapy methods, Female, Humans, Male, Occupational Diseases diagnosis, Occupational Diseases etiology, Patient Education as Topic methods, Prospective Studies, Range of Motion, Articular, Sweden, Treatment Outcome, Back Pain therapy, Behavior Therapy standards, Exercise Therapy standards, Occupational Diseases therapy, Patient Education as Topic standards
- Abstract
The aim of this study was to determine whether graded activity restored occupational function in industrial blue-collar workers who were sick-listed for 8 weeks because of subacute, nonspecific, mechanical low back pain (LBP). Patients with LBP, who had been examined by an orthopedic surgeon and a social worker, were randomly assigned to either an activity group (n = 51) or a control group (n = 52). Patients with defined orthopedic, medical, or psychiatric diagnoses were excluded before randomization. The graded activity program consisted of four parts: (1) measurements of functional capacity; (2) a work-place visit; (3) back school education; and (4) an individual, submaximal, gradually increased exercise program, with an operant-conditioning behavioral approach, based on the results of the tests and the demands of the patient's work. Records of the amount of sick leave taken over a 3-year period (ie, the 1-year periods before, during, and after intervention) were obtained from each patient's Social Insurance Office. The patients in the activity group returned to work significantly earlier than did the patients in the control group. The median number of physical therapist appointments before return to work was 5, and the average number of appointments was 10.7 (SD = 12.3). The average duration of sick leave attributable to LBP during the second follow-up year was 12.1 weeks (SD = 18.4) in the activity group and 19.6 weeks (SD = 20.7) in the control group. Four patients in the control group and 1 patient in the activity group received permanent disability pensions. The graded activity program made the patients occupationally functional again, as measured by return to work and significantly reduced long-term sick leave.
- Published
- 1992
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.